Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Titel:
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Auteur:
Remon, J. Besse, B. Aix, S. Ponce Callejo, A. Al-Rabi, K. Bernabe, R. Greillier, L. Majem, M. Reguart, N. Monnet, I. Cousin, S. Garrido, P. Robinet, G. Garcia Campelo, R. Madroszyk, A. Mazières, J. Curcio, H. Wasąg, B. Pretzenbacher, Y. Fournier, B. Dingemans, A.-M.C. Dziadziuszko, R.